PMID- 37343509
OWN - NLM
STAT- MEDLINE
DCOM- 20230714
LR  - 20230718
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 17
IP  - 7
DP  - 2023 Jul
TI  - Effect of dipeptidyl peptidase-4 inhibitors on glycated hemoglobin levels relies 
      on dietary sodium intake.
PG  - 102806
LID - S1871-4021(23)00102-9 [pii]
LID - 10.1016/j.dsx.2023.102806 [doi]
AB  - AIMS: Sodium load increases endogenous glucagon-like peptide-1 (GLP-1) levels in 
      humans. Therefore, patients with an increased amount of dietary sodium intake are 
      supposed to have higher endogenous GLP-1 levels compared to those with less 
      dietary sodium intake. Therefore, it can be hypothesized that patients with type 
      2 diabetes mellitus (T2DM) with more dietary sodium intake show better dipeptidyl 
      peptidase-4 inhibitor (DPP-4i) effect on glycemic control because of the expected 
      higher GLP-1 level. Thus, we performed a single-center cohort study to explore 
      this idea. METHODS: Medical records of patients with T2DM prescribed DPP-4i in 
      the last 11 years were investigated. Dietary sodium intake was measured before 
      the DPP-4i prescription with Tanaka's formula using casual spot urine samples. 
      The effect of DPP-4i on glycemic control was estimated by the subtraction of 
      glycated hemoglobin (HbA1c) before DPP-4i initiation from HbA1c 1 year after 
      DPP-4i administration. We analyzed 50 patients. RESULTS: DPP-4i improved HbA1c 
      by -0.41% +/- 0.66%. The effect of DPP-4i on glycemic control was significantly 
      negatively correlated with the dietary sodium intake (r = -0.400). Thus, the more 
      dietary sodium intake, the better the glycemic control by DPP-4i. CONCLUSIONS: 
      Thus, patients can expect better plasma glucose control by DPP-4is if patients 
      are taking increased dietary sodium intake.
CI  - Copyright (c) 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National 
      Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. 
      All rights reserved.
FAU - Okada, Shuichi
AU  - Okada S
AD  - Hidaka Hospital, 886 Nakao-machi Takasaki, Gunma, 370-0001, Japan. Electronic 
      address: okadash1823@gmail.com.
FAU - Okada, Kazuya
AU  - Okada K
AD  - Department of Orthopedic Surgery, Gunma University, 3-39-15 Showa-machi, 
      Maebashi, Gunma, 371-8511, Japan.
FAU - Okada, Junichi
AU  - Okada J
AD  - Department of Medicine, Division of Endocrinology, Albert Einstein College of 
      Medicine, 1301 Morris Park Ave., Price 369, Bronx, NY, 10461, USA.
FAU - Kikkawa, Koji
AU  - Kikkawa K
AD  - Hidaka Hospital, 886 Nakao-machi Takasaki, Gunma, 370-0001, Japan.
FAU - Yamada, Eijiro
AU  - Yamada E
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Maebashi, Gunma, 371-8511, Japan.
FAU - Saito, Tsugumichi
AU  - Saito T
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Maebashi, Gunma, 371-8511, Japan.
FAU - Andou, Tetsuro
AU  - Andou T
AD  - Hidaka Hospital, 886 Nakao-machi Takasaki, Gunma, 370-0001, Japan.
FAU - Ohshima, Kihachi
AU  - Ohshima K
AD  - Hidaka Hospital, 886 Nakao-machi Takasaki, Gunma, 370-0001, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230615
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Hypoglycemic Agents)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases)
RN  - 0 (Sodium, Dietary)
SB  - IM
MH  - Humans
MH  - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use/pharmacology
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glycated Hemoglobin
MH  - Cohort Studies
MH  - Hypoglycemic Agents
MH  - Glucagon-Like Peptide 1
MH  - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
MH  - *Sodium, Dietary
OTO - NOTNLM
OT  - Dietary sodium intake
OT  - Dipeptidyl peptidase 4 inhibitor
OT  - Glycated hemoglobin
OT  - Type 2 diabetes mellitus
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/06/22 01:07
MHDA- 2023/07/14 13:06
CRDT- 2023/06/21 18:09
PHST- 2023/03/06 00:00 [received]
PHST- 2023/06/04 00:00 [revised]
PHST- 2023/06/06 00:00 [accepted]
PHST- 2023/07/14 13:06 [medline]
PHST- 2023/06/22 01:07 [pubmed]
PHST- 2023/06/21 18:09 [entrez]
AID - S1871-4021(23)00102-9 [pii]
AID - 10.1016/j.dsx.2023.102806 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2023 Jul;17(7):102806. doi: 10.1016/j.dsx.2023.102806. Epub 
      2023 Jun 15.